Breakthrough Therapy Designation was based on results from the Phase I/II RAINFOL-01 trial, which showed encouraging clinical ...

In this video interview, Sunny Kumar, MD, partner at Informed Ventures, explains how high upfront costs and limited proof of ...

Craig Lipset, co-chair, Decentralized Trials & Research Alliance (DTRA), and Kyle McAllister, co-founder, CEO, Trially, ...

Strategic AI applications are helping life sciences teams overcome hidden bias, accelerate data discovery, and improve ...

Ampreloxetine is being developed to address the root cause of blood pressure instability in multiple system atrophy, aiming ...

The FDA will now publish adverse event data from FAERS on a daily basis, marking a major step toward greater transparency in drug development.

In this video interview, Caroline Potts, general manager of sites and patient services at Medical Research Network (MRN), ...

Results from the first part of a Phase I/II trial (NCT06569823) showed that Z-1018 generated immune responses comparable to ...

The Supreme Court has ruled 5-4 to allow the Trump administration’s NIH funding cuts to continue, impacting more than 1,700 ...

Results from the Phase II OptiTROP-Lung01 trial (NCT05351788) showed that Sichuan Kelun-Biotech’s sac-TMT combined with ...

In this episode of the Applied Clinical Trials Brief, we recap our three most-viewed stories of the week—covering the Supreme Court’s decision to uphold NIH funding cuts tied to DEI, Phase II data ...

A new exploratory study will evaluate the safety of Anktiva in patients with long COVID, with secondary and exploratory ...